104¦~5¤ë¸¹ ¹D ªk ªk °T (277)

DEEP & FAR

 

 

 

ANDA-½×¤ÎÃľDzզXª«»P²Ä¤K±øÁn©ú

~Fed. Cir.2012 (¤Q¤»)

 

 

³¯ºaºÖ ±M§Q¥N²z¤H

¡E¤¤°êÂåÃľǰ|ÃľǨt¾Ç¤h

¡E¤é¥»ºÖ©£¤j¾Ç¥ÍÃľǩҺӤh

¡E¶§©ú¤j¾ÇÂå¾ÇÃIJz©Ò³Õ¤h

 

ªü´µ§Q±¶§Q±d¦]¦¹ÅGºÙ¤£À³¤ñ·ÓWarner-Lambert®×¡A¦Ó¤£·|±j­¢¥»°|­n±Æ°£¤@¤Á¡A®Ú¾Ú¡± 271(e)(2) ¥Î³~±M§Q¤èªk¤§½Ð¨D¡A¥B¨äANDA¨Ã¥¼©ú½T¦a±Ô­z±M§Q¤§¤èªk(Warner-Lambert is inapposite and does not compel us to preclude all ¡± 271(e)(2) claims based on method of use patents where the ANDA does not expressly recite a patented method.)¡C³o¨ÇÅG¸Ñ¤_¨ÆµL¸É¡C

¦bWarner-Lambert¤§±M§Q¡A«Y½Ð¨D¤@ºØ«D¼ÐÅÒ¤§¥Î³~ÃĪ«¤§Æ[ÂI¡AÁöµM Astra Zeneca«Y¥¿½T¦a¡A¦Ó¨ä°Ï§O»P ¡± 271(e)(2) µLÃö¡C·í¦Ò¼{»¼¥æANDA«I¥Ç¤@ºØ±M§Q¤èªk¤§«ü±±¡A¡± 271(e)(2) ¾É¤Þ¥»°|¡A°w¹ïANDA©Ò´M¨D®Ö­ã¤§½d³ò¶i¦æ¤ÀªR ¡Xªk³W¬É©w»¼¥æANDA¤§«IÅv¦æ¬°«Y¡¨¤@ºØ¤w¦b±M§Q©Ò½Ð¨D©Î±M§Q©Ò©Ò´M¨D¨DÃĪ«¤§¨Ï¥Î¡¨¡C (the statute de-fines the infringing act as filing an ANDA for ¡§a drug claimed in a patent or the use of which is claimed in a patent.¡¨ [1])

 



[1]. 35 U.S.C. ¡± 271(e)(2)(A).